Patent ID: 7939551
Filing Date: 2011-05-10
Classification: A61K,A61P,Y10S

Abstract:
1. A pharmaceutical composition, said composition comprising: i) a compound having the formula (I) or a pharmaceutically acceptable salt thereof: wherein Ar X is a divalent linkage selected from the group consisting of (C wherein R Y is a divalent linkage selected from the group consisting of alkylene, —O—, —C(O)—, —N(R wherein R R wherein R R R the subscript p is an integer of from 0 to 3; and the subscript q is an integer of from 1 to 2; and R R ii) one or more antidiabetic agents, or pharmaceutically acceptable salts of said one or more antidiabetic agents; wherein said antidiabetic agent is a member selected from the group consisting of a sulfonylurea, an α-glucosidase inhibitor, a potassium channel antagonist, an aldose reductase inhibitor, insulin and insulin analogs, and mixtures thereof; wherein the sulfonylurea is a member selected from the group consisting of acetohexamide, chlorpropamide, glyburide, glipizide, gliclazide, glimepiride, gliquidone, glisoxepid, glibornuride, gliamilide, glicetanile, gliflumide, glymidine, glyparamide, tolpyrramide, glyhexamide, phenbutamide, tolazamide, tolbutamide and tolcyclamide; the α-glucosidase inhibitor is a member selected from the group consisting of acarbose, miglitol, emiglitate, voglibose, MDL-25,637, camiglibose and MDL-73,945; the potassium channel antagonist is repaglinide; the aldose reductase inhibitor is a member selected from the group consisting of zopolrestat, minalrestat, ponalrestat and tolrestat; the insulin or insulin analog is a member selected from the group consisting of LysPro insulin, GLP-1 (7-37) insulinotropin, GLP-1 (7-36)-NH and optionally a pharmaceutically acceptable carrier or diluent.